Literature DB >> 8145920

The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro.

A J Windebank1, A G Smith, J W Russell.   

Abstract

Cisplatin, used to treat ovarian, bladder, and testicular cancers, causes a sensory dose-limiting neuropathy. Preliminary observations in humans and animals suggest that nerve damage may be prevented by ACTH analogs, particularly those belonging to the melanocortin class, and by nerve growth factor (NGF). We established a rat embryo dorsal root ganglion model to study cisplatin neurotoxicity. The drug reproducibly inhibited axonal growth at concentrations similar to that known to produce toxicity in neurons. The inhibition was prevented in a dose-dependent fashion by simultaneous exposure to alpha-melanocyte stimulating hormone (alpha-MSH) or ACTH but not by excess NGF or ciliary neurotrophic factor (CNTF). The ACTH peptides were not effective in preventing suramin-induced neurotoxicity in the same model. Drug interaction and dose-response studies showed that ACTH and alpha-MSH do not act by potentiation of NGF action. ACTH analogs appear to protect against cisplatin-induced neurotoxicity directly at the cellular level.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145920     DOI: 10.1212/wnl.44.3_part_1.488

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons.

Authors:  Nathan P Staff; Jewel L Podratz; Lukas Grassner; Miranda Bader; Justin Paz; Andrew M Knight; Charles L Loprinzi; Eugenia Trushina; Anthony J Windebank
Journal:  Neurotoxicology       Date:  2013-09-12       Impact factor: 4.294

2.  Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration.

Authors:  G Tredici; S Tredici; D Fabbrica; C Minoia; G Cavaletti
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

3.  Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients.

Authors:  A Pace; L Bove; C Nisticò; M Ranuzzi; P Innocenti; A Pietrangeli; E Terzoli; B Jandolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

Review 4.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 5.  Interventions for preventing neuropathy caused by cisplatin and related compounds.

Authors:  James W Albers; Vinay Chaudhry; Guido Cavaletti; Ross C Donehower
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

6.  Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy.

Authors:  A A Geldof
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice.

Authors:  Lauren E Ta; Allan J Bieber; Susan M Carlton; Charles L Loprinzi; Philip A Low; Anthony J Windebank
Journal:  Mol Pain       Date:  2010-03-05       Impact factor: 3.395

8.  Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity.

Authors:  W F Goins; K A Lee; J D Cavalcoli; M E O'Malley; S T DeKosky; D J Fink; J C Glorioso
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Authors:  S Koeppen; C C P Verstappen; R Körte; M E Scheulen; D Strumberg; T J Postma; J J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; H C Diener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553

10.  Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle.

Authors:  J S Gill; A J Windebank
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.